TY - JOUR
T1 - Isolation and characterisation of lymphatic endothelial cells from lung tissues affected by lymphangioleiomyomatosis
AU - Nishino, Koichi
AU - Yoshimatsu, Yasuhiro
AU - Muramatsu, Tomoki
AU - Sekimoto, Yasuhito
AU - Mitani, Keiko
AU - Kobayashi, Etsuko
AU - Okamoto, Shouichi
AU - Ebana, Hiroki
AU - Okada, Yoshinori
AU - Kurihara, Masatoshi
AU - Suzuki, Kenji
AU - Inazawa, Johji
AU - Takahashi, Kazuhisa
AU - Watabe, Tetsuro
AU - Seyama, Kuniaki
N1 - Funding Information:
The study was supported in part by the LAM foundation Pilot Award – LAM0119E01-16 (Seyama K), a Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology (16K09589; Seyama K), and a grant from the Intractable Respiratory Diseases and Pulmonary Hypertension Research Group from the Ministry of Health, Labour, and Welfare, Japan (Seyama K). English writing was proofread and edited by Ms. Elaine Blumberg.
Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12
Y1 - 2021/12
N2 - Lymphangioleiomyomatosis (LAM) is a rare pulmonary disease characterised by the proliferation of smooth muscle-like cells (LAM cells), and an abundance of lymphatic vessels in LAM lesions. Studies reported that vascular endothelial growth factor-D (VEGF-D) secreted by LAM cells contributes to LAM-associated lymphangiogenesis, however, the precise mechanisms of lymphangiogenesis and characteristics of lymphatic endothelial cells (LECs) in LAM lesions have not yet been elucidated. In this study, human primary-cultured LECs were obtained both from LAM-affected lung tissues (LAM-LECs) and normal lung tissues (control LECs) using fluorescence-activated cell sorting (FACS). We found that LAM-LECs had significantly higher ability of proliferation and migration compared to control LECs. VEGF-D significantly promoted migration of LECs but not proliferation of LECs in vitro. cDNA microarray and FACS analysis revealed the expression of vascular endothelial growth factor receptor (VEGFR)-3 and integrin α9 were elevated in LAM-LECs. Inhibition of VEGFR-3 suppressed proliferation and migration of LECs, and blockade of integrin α9 reduced VEGF-D-induced migration of LECs. Our data uncovered the distinct features of LAM-associated LECs, increased proliferation and migration, which may be due to higher expression of VEGFR-3 and integrin α9. Furthermore, we also found VEGF-D/VEGFR-3 and VEGF-D/ integrin α9 signaling play an important role in LAM-associated lymphangiogenesis.
AB - Lymphangioleiomyomatosis (LAM) is a rare pulmonary disease characterised by the proliferation of smooth muscle-like cells (LAM cells), and an abundance of lymphatic vessels in LAM lesions. Studies reported that vascular endothelial growth factor-D (VEGF-D) secreted by LAM cells contributes to LAM-associated lymphangiogenesis, however, the precise mechanisms of lymphangiogenesis and characteristics of lymphatic endothelial cells (LECs) in LAM lesions have not yet been elucidated. In this study, human primary-cultured LECs were obtained both from LAM-affected lung tissues (LAM-LECs) and normal lung tissues (control LECs) using fluorescence-activated cell sorting (FACS). We found that LAM-LECs had significantly higher ability of proliferation and migration compared to control LECs. VEGF-D significantly promoted migration of LECs but not proliferation of LECs in vitro. cDNA microarray and FACS analysis revealed the expression of vascular endothelial growth factor receptor (VEGFR)-3 and integrin α9 were elevated in LAM-LECs. Inhibition of VEGFR-3 suppressed proliferation and migration of LECs, and blockade of integrin α9 reduced VEGF-D-induced migration of LECs. Our data uncovered the distinct features of LAM-associated LECs, increased proliferation and migration, which may be due to higher expression of VEGFR-3 and integrin α9. Furthermore, we also found VEGF-D/VEGFR-3 and VEGF-D/ integrin α9 signaling play an important role in LAM-associated lymphangiogenesis.
UR - http://www.scopus.com/inward/record.url?scp=85104424827&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85104424827&partnerID=8YFLogxK
U2 - 10.1038/s41598-021-88064-3
DO - 10.1038/s41598-021-88064-3
M3 - Article
C2 - 33863980
AN - SCOPUS:85104424827
SN - 2045-2322
VL - 11
JO - Scientific Reports
JF - Scientific Reports
IS - 1
M1 - 8406
ER -